Carboplatin

Catalog No.S1215 Synonyms: JM-8, CBDCA, NSC 241240

Carboplatin Chemical Structure

Molecular Weight(MW): 371.25

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

Size Price Stock Quantity  
USD 77 In stock
USD 107 In stock
USD 167 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 18 Publications

5 Customer Reviews

  • Detection of apoptotic responses was found to increase in epimorphin-treated  A1847 with increasing concentrations of carboplatin compared to those of the untreated controls. Data were normalized to the controls and are represented as means ± S.D. [*p<0.05 compared with control]. Images of apoptotic cells were captured at 10X magnification, with at least 3 images per well, using an upright phase-contrast microscope (T3.15A; Fisher Scientific).

    PLoS One 2012 8, e72637. Carboplatin purchased from Selleck.

  • A. MCF10A-Ras overexpressing a vector control or the gene of interest (GeneX), or MCF7 expressing a scramble or a siRNA for the geneX were treated with DMSO or with Carboplatin for 24h. Resistant colonies were allowed to grow for 2 weeks, and are then stained with Crystal Violet. B. Quantification of the results.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

  • Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Carboplatin for 48h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

  • Cell lines were exposed to the indicated concentrations of carboplatin (A) for 72 hours. Cell viability was assessed by alamarBlue assay and data recorded as fluorescence units at 590 nm. Data are presented as mean μM ± S.E.M. required to inhibit cell viability by 50%, in a minimum of three independent experiments.

    Cancer Lett, 2018, 436:75-86. Carboplatin purchased from Selleck.

  • (A) The BRCA1-mutated TNBC cell lines MDA-MB-436 and HCC1937 were treated with CBP (10 μM) plus GEM (100 nM) combined with or without olaparib (10 μM) for the indicated times, and then, the cell viability was determined with an MTT assay. The results show data from six independent experiments expressed as the mean ± SD. p < 0.05.

    Sci Rep, 2017, 7:42319. Carboplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.
Features A DNA synthesis inhibitor.
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  NV7sW3R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[2[mFuOi1{NfMAje69VQ>? MX23NkBp NGjMW3RqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NFLPSmgzPjF|N{GwOS=>
Tca8113/CBP  NGLwUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n1XVIuOjYkgJpOwG0> NHXrNW04OiCq NITy[5lqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MVmyOlE{PzFyNR?=
Tca8113/PYM  Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3XNk0zPeLCid88US=> MUS3NkBp MXfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M{TqdlI3OTN5MUC1
SKOV3 NHzmR2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXO2NEBu\y:vbB?= NWGweFJxOS13IHS= M2TGR4lvcGmkaYTzJINmdGxidnnhZoltcXS7IITpcYUh\GWyZX7k[Y51dHl? NXzMb41EOjZzM{ewOFM>
SKOV3 M3;jSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HoZVAuPCEQvHevcYw> M37Ce|I1NzR6L{eyJIg> MmjJbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? MlP0NlYyOjV{N{O=
SKOV3 M2f2ZWFxd3C2b4Ppd{BCe3OjeR?= NV7rfoFOOiEQvHevcYw> MnSyOFghcA>? Mn;KbY5lfWOnczDhdI9xfG:|aYO= MXWyOlEzPTJ5Mx?=
OSA MUjDcI9vd2enbnnjJGF{e2G7 MnHBNk42NzVizszN MXry[ZN2dHS|IHnuJIxwf2W{IHPvcI9vgSCob4LtZZRqd25iYYOgZ49ueGG{ZXSgeI8h\Wm2aHXyJGJOUTFic3nSUmEhfHKnYYTt[Y51 NY\ScGxvOjZzMUC2NlA>
A549 MlzTSpVkfGmxbjDBd5NigQ>? Mn36NE8zPS93MDFOwG0> Mmr5NlQhcA>? NHTnbWZld3ewcnXneYxifGW|IH3pVk0zODViZYjwdoV{e2mxbtMg MXqyOVkyPzNzNx?=
H1975 MnLjSpVkfGmxbjDBd5NigQ>? M{XlfVAwOjVxNUCg{txO NUfaXFhnOjRiaB?= Mojm[I94dnKnZ4XsZZRmeyCvaWKtNlA2KGW6cILld5Nqd28EoB?= M3jDO|I2QTF5M{G3
A549 NVvSc2h4TnWldHnvckBCe3OjeR?= NWjjfoZ{OC9{NT:1NEDPxE1? NET2WGkzPCCq NWnBcZdIfXC{ZXf1cIF1\XNibXnSMVIyQCCneIDy[ZN{cW:w MXuyOVkyPzNzNx?=
H1975 MX7GeYN1cW:wIFHzd4F6 NHjNUpcxNzJ3L{WwJO69VQ>? NGfPWXgzPCCq NInCVHZ2eHKnZ4XsZZRmeyCvaWKtNlE5KGW6cILld5Nqd25? MX[yOVkyPzNzNx?=
A549 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnq3NlUh|ryP MoHNNlQhcA>? NGjFSGtqdmirYnn0d{Bk\WyuIHfyc5d1cA>? NHzDOXQzPTlzN{OxOy=>
H1975 NXS4WXJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PNZ|I2KM7:TR?= MlizNlQhcA>? NXiwcZJkcW6qaXLpeJMh[2WubDDndo94fGh? MUCyOVkyPzNzNx?=
MDA-MB-231 MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jRTVAuOjJyIN88[{9udA>? MYC3NkBp M4[2bmlEPTEEoE2gPFYh|ryP NYXPXGlFOjV6M{e2PVE>
T47D MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPxN3hPOC1{MkCg{txoN22u M1PodlczKGh? NVfQ[3B{UUN3MNMgQUA1QC57IN88US=> Mo\LNlU5Ozd4OUG=
LCTCC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHVUoF5UUN3ME2zMljjiIoEtV2= M{W5c|I2Pzd|MU[3
MCTCC NWrLeGZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGGwSWlKSzVyPUKuPQKBkcL3TR?= M{nQXVI2Pzd|MU[3
MegTCC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXDTXcyUUN3ME20MlHjiIoEtV2= NE\QXWUzPTd5M{G2Oy=>
MonoTCC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfPNmdKSzVyPUWuOwKBkcL3TR?= MXqyOVc4OzF4Nx?=
MCF7 MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfONlAh|ryP NXHVOYxoPzJiaB?= NICxOYNqdmS3Y3XzJINmdGxiZHXheIghd2ZiSGCx{tIu\GWybHX0[YQhVUOINzDj[Yxtew>? MmG2NlU4PjlyMkW=
A-549  MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKwMlUh|ryP NVLzXGFLOjRiaB?= M2PDNGROW00EoB?= NWrsXYQ4cW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=> M3KyS|I2PzV3Nkmw
A-549  MoDHRZBweHSxc3nzJGF{e2G7 NYrpelVCOC53IN88US=> NEC5XHQ1QCCq NIrhc5RFVVORwrC= NFHueZd{cG:5czDlZZJtgSCjcH;weI9{cXNiZnXheJVz\XNiaX7jcJVlcW6pIHLs[YJjcW6pIHHu[EBkcHKxbXH0bY4h[2:wZHXud4F1cW:w NWfyUoV6OjV5NUW2PVA>
A-549  NI[xXGZHfWO2aX;uJGF{e2G7 NUCxVmJFOC53IN88US=> NUD2bJdSPDhiaB?= Mlv1SG1UV8Li M1TL[ZNpd3e|IHHi[ZJz[W62IH3pZ5JwfHWkdXzlJIRqe3K3cITpc44> NEj1TIEzPTd3NU[5NC=>
A-549  M334W2Z2[3Srb36gRZN{[Xl? NVXmVIdGOC53IN88US=> NVHBV|hIPDhiaB?= M3K3cmROW00EoB?= M4rsU4lvcGmkaYTzJI9nKGOnbHygcYloemG2aX;uxsA> NV:5c2d6OjV5NUW2PVA>
RMG-1 NU\tVFY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DQXWlEPTB;MkiuPEDDuSB|Lk[gcYcwVA>? NHrFR5QzPTd{NkmxNy=>
FN-RMG-1 NED0NYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;rTWM2OD12MD61JOKyKDRwMjDt[{9NEiEQvF2= NXHFPZFVOjV5Mk[5NVM>
RMG-1-hFUT NVz2W2h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[1VGFKSzVyPUW4MlEhyrFiMj60JI1oN0x? M2C2ZVI2PzJ4OUGz
FN-RMG-1-hFUT MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTFzOD64JOKyKDF|LkigcYcwVA>? M3;3ZlI2PzJ4OUGz
CHP-134  MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXPVnIyKM7:TR?= NHHIN4xFVVORwrC= M2TEfIlvcGmkaYTzJJNq\26rZnnjZY51KGOnbHyg[5Jwf3SqIHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? NVXzSIxFOjV4NUi0OlM>
IMR-32 NVriUpFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2i4W|Eh|ryP M3X2emROW00EoB?= NFn3d49qdmirYnn0d{B{cWewaX\pZ4FvfCClZXzsJIdzd3e2aDDjc41jcW6nZDD3bZRpKEeVS{K4N|A{PzF? M2Tvb|I2PjV6NE[z
CHP-134  NFfYN5dHfWO2aX;uJGF{e2G7 NEDGemgyOCEQvF5CpC=> NVO3Zoo1TE2VT9Mg MljNbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJGdUUzJ6M{CzO|E> M1TYdFI2PjV6NE[z
IMR-32 MVXGeYN1cW:wIFHzd4F6 MXexNEDPxE4EoB?= MkLCSG1UV8Li NVi3UoVKcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKEeVS{K4N|A{PzF? MYGyOVY2QDR4Mx?=
A549 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlq1NE4zNTRyMECg{txO MkfuO|IhcA>? NVrXdm92UUN3ME2xNlYhyrFiNT6wJO69VQ>? NXHHOHRqOjV4MkWyOFM>
A549/CDDP M1\adGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVq5bWptOC5{LUSwNFAh|ryP NVHETJdVPzJiaB?= MW\JR|UxRTJ2MNMgxtHDqDR3Lkeg{txO NGrEUoUzPTZ{NUK0Ny=>
H460  NX76UottT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3GwOVI1KGh? M1vPRWROW09? M2jrc2lEPTB;Nz65JO69VQ>? MkP3NlU2QTl7OUW=
H460  MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:3Mlkh|ryP NVXxRmxEOjRiaB?= NWXXSIFUTE2VTx?= NWDocFRHe2ixd4OgZUBz[WSrb4PlcpNqfGm8aX7nJIVn\mWldDD0c{BZNXKjeYO= MoPjNlU2QTl7OUW=
NRK-52E MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHWS3c4OsLiaNMg NEDnfWxKSzVyPUGwNEDDuSBzMj65JO69VQ>? M13XOVI2PTZ3NkCz
RGE MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:3NuKhcMLi M2j6ZWlEPTB;MkKgxtEhPy52IN88US=> NUHtbZp7OjV3NkW2NFM>
NRK-52E NXX3TG9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYG3NuKhcMLi MXjJR|gxRTF5OTFCtUA6NjVizszN NWPJXoY5OjV3NkW2NFM>
RGE NF\ydVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX6Vog4OsLiaNMg MWDJR|gxRTZ|INMxJFcvPCEQvF2= MmL5NlU2PjV4MEO=
SK-OV-3 NYXqT4syT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj1TIszPzJiaB?= M1HKRmlEPTB;MUC0Mlgh|ryP Mn3RNlU2OjBzM{K=
ES-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jRWlczKGh? Mn7LTWM2OD1zND62JO69VQ>? M{XuU|I2PTJyMUOy
OVCAR-8 MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFyyVpk4OiCq MY\JR|UxRTl4LkCg{txO NFv1TZMzPTV{MEGzNi=>
3AO M3XN[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\Md3d2PzJiaB?= NGTud|lKSzVyPU[zMlQh|ryP NU\OT49xOjV3MkCxN|I>
A2780 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvLfIdqPzJiaB?= NWDkZ21FUUN3ME2xOFUvPyEQvF2= NVv2XFVXOjV3MkCxN|I>
SW626 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYG3NkBp NWPEOIpYUUN3ME25O{4xKM7:TR?= MWOyOVUzODF|Mh?=
OVCAR-3 NXrHUGluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTmZnE4OiCq NYrUeGxMUUN3ME2zNk43KM7:TR?= NF7venAzPTV{MEGzNi=>
A549 M4mzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVW3do9[UUN3ME2xOVEvPTZiwsGgOVMvODZizszN M1vmbFI2Ojd5NE[x
4T1 NHOzfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nqTWlEPTB;OESuOlIhyrFiM{CuNFUh|ryPCjFOwG0> NH;Kd4IzPTJ5N{S2NS=>
BALB/3T3 M3rsWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjPTWM2OD1zND6zNEDDuSB4Lk[4JO69VQ>? Mnq5NlUzPzd2NkG=
B16 NWOyRpc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojhTWM2OD14ND6zNEDDuSB4LkixJO69VQ>? MYeyOVI4PzR4MR?=
DU 145 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHCTWM2OD1|NT6wOEDDuSBzNz61OEDPxE1? M{\Ic|I2Ojd5NE[x
FaDu MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYL0XYk4UUN3ME20OU4{QSEEsTCxNU42OCEQvF2= M2fDeFI2Ojd5NE[x
HCV-29T MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LvdWlEPTB;NEiuOVchyrFiMkKuOFkh|ryP M3SxXFI2Ojd5NE[x
HL-60 M2TIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofyTWM2OD1zMT6xNEDDuSB2LkS3JO69VQ>? MWCyOVI4PzR4MR?=
HT-29 NVXab4FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\T[ZBKSzVyPUi5MlE3KMLzIEG4Mlg3KM7:TR?= NV6zdmg1OjV{N{e0OlE>
H146 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTR7LkdCtVE{NjFizszN NEC5bGozPTF{NEK4Ni=>
H187 Ml7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTF{LkhCtVIvPyEQvF2= M1O1TlI2OTJ2Mkiy
H128 NUn4e3J4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPGcJFKSzVyPUGwOk41yrF7Lk[g{txO NIjUWpEzPTF{NEK4Ni=>
H69 NHW5XYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTd4LkpCtVI4NjhizszN MUGyOVEzPDJ6Mh?=
H209 MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPmTWM2OD1{NUiuNeKyQTlwODFOwG0> MmjxNlUyOjR{OEK=
DMS153 M3GyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfkTWM2OD13Nz64xtE6NjJizszN NFXDfYEzPTF{NEK4Ni=>
H526 NWXPUnBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;DemlEPTB;Nz6yxtEyNjdizszN NWrOToxkOjVzMkSyPFI>
DMS114 NXHJZWVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXRXYRKSzVyPUi1MljDuTF{Lkig{txO M{i1eFI2OTJ2Mkiy
DMS53 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HSWGlEPTB;MUS2MlLDuTN4LkSg{txO NFLw[VkzPTF{NEK4Ni=>
HeLa MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVqxc5BVPS16MDFOwG0> MYHpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MXiyOVExQTN4MB?=
MCF-7 MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfKOU05OCEQvF2= M3Tt[IlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NYPWWXpGOjVzMEmzOlA>
MDA-MB-231 Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvNOU05OCEQvF2= NV7TTXR[cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MUiyOVExQTN4MB?=
CaOV3 MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrLfmc4OiCq MU\JR|UxRTh4LkGg{txO M2\EdVI2ODZ6OES5
OVCAR-3 NYHzfGFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLSO|IhcA>? NFTXXIZKSzVyPUG3PU42KM7:TR?= MWmyOVA3QDh2OR?=
OVCAR-5 NFvFT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVK3NkBp MoLJTWM2OD15NT63JO69VQ>? NITTToQzPTB4OEi0PS=>
SKOV-3 Mki2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDKO|IhcA>? NIfVdHdKSzVyPUWwOEDPxE1? NVnpRYs{OjVyNki4OFk>
OVCAR-4 M3zTZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LiR|czKGh? MVLJR|UxRTJ7MD62JO69VQ>? NHHiRWUzPTB4OEi0PS=>
OVCAR-8 NIrFWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX1Rmh6PzJiaB?= MlnHTWM2OD14OUCuNkDPxE1? M{TuPVI2ODZ6OES5
MA148 NW\WN5EzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:yOEBp NHTaNXNKSzVyPUizMlbjiIoEsfMAjVEvPCEQvHevcYw> MmfLNlQ5OzFyOUG=
A549 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T5RlI1KGh? MlHjTWM2OD15N{[uNQKBkcLz4pEJNU46KM7:Zz;tcC=> NWTIU4FFOjR6M{GwPVE>
MDA-MB-231 NUP0OXljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XxV|I1KGh? NGj1enJKSzVyPUe0PE4x6oDLwsJihKkyNjFizsznM41t NHTzZmczPDh|MUC5NS=>
NCI-ADR/RES  M{LweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[yOEBp MXzJR|UxRTF5NUOuNQKBkcLz4pEJOE41KM7:Zz;tcC=> MWWyOFg{OTB7MR?=
MA148 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PiVVQ5KGh? Mo\FTWM2OD1{OD6x5qCKyrIkgJmxMlAh|rypL33s NYnJTYV6OjR6M{GwPVE>
A549 NX30RZZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XRSlQ5KGh? NHrlU2pKSzVyPUGxPE4x6oDLwsJihKkyNjJizsznM41t NXPONHBNOjR6M{GwPVE>
MDA-MB-231 NUDp[VFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[0PEBp MYfJR|UxRTF6Mz6w5qCKyrIkgJmxMlIhKM7:Zz;tcC=> NInXbIwzPDh|MUC5NS=>
NCI-ADR/RES  NXvzcI94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrwPJY1QCCq NYTBU3Q3UUN3ME2xPVMvOOLCidMx5qCKOS57IN88[{9udA>? NUTLN|FEOjR6M{GwPVE>
MA148 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknqO|IhcA>? NED4V2FKSzVyPUGzMlfjiIoEsfMAjVEvOiEQvHevcYw> NGfvZ3MzPDh|MUC5NS=>
A549 M{DCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXsO|IhcA>? MUTJR|UxRTZ2LkRihKnDueLCiUGuNUDPxGdxbXy= MonXNlQ5OzFyOUG=
MDA-MB-231 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPFOHNSPzJiaB?= NXTScGFwUUN3ME25PU426oDLwsJihKkyNjFizsznM41t NFrDfGszPDh|MUC5NS=>
NCI-ADR/RES  NXLvU2dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;NcZJGPzJiaB?= NX\zfZlKUUN3ME2zO{416oDLwsJihKkyNjdizsznM41t MmXBNlQ5OzFyOUG=
A549 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fWblczKGh? NHPINoJFVVOR NGLETolKSzVyPUG1Nk41ODlizszN MmD6NlQ4OjF|MkO=
NCI-H157 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWi3NkBp MXHEUXNQ MVTJR|UxRTh7Lkm3O{DPxE1? MlroNlQ4OjF|MkO=
PC9 NYqwcY1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3foclczKGh? NYC5eXhLT0N3ME23NU43yrF7LkWgxtVO M3fUWFI1PjF6OEC5
A549  MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVS0[IR7PzJiaB?= NEjuWFJISzVyPUGzOuKyOzFwNjFCuW3DqA>? MV2yOFYyQDhyOR?=
PC9 Mn;pRZBweHSxc3nzJGF{e2G7 NYnVRYVWOTByINM1US=> M2f0flczKGh? MoqwbY5lfWOnczDhdI9xfG:|aYO= MmjhNlQ3OTh6MEm=
A549  MkDQRZBweHSxc3nzJGF{e2G7 MWCxNFAhyrWP NYjKSpV1PzJiaB?= M{ntPIlv\HWlZYOgZZBweHSxc3nz Mm\DNlQ3OTh6MEm=
A549 NXzidoN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;xPVI1KGh? NYXZUVV{UUNzME2xMlQ4PiCwTR?= MXSyOFM6PjR|Nx?=
H1299 MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnqNlQhcA>? M{HSfGlEOTB;MD60OFMhdk1? MoXtNlQ{QTZ2M{e=
HCC15 M1\ZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXuyOEBp NY\r[o5oUUNzME2wMlM1PiCwTR?= NIfNWIozPDN7NkSzOy=>
H157 NXPlUot6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHi1dFgzPCCq M{OxXmlEOTB;MD64NUBvVQ>? M{fZSVI1Ozl4NEO3
A2780 MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37kPGlEPTB;MUSuNQKBkcLz4pEJNU41KM7:TR?= NX;Xc2MxOjR{MEm2PVM>
A2780cisR Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fYTWlEPTB;NEiuPgKBkcLz4pEJN{46KM7:TR?= M4nJcVI1OjB7Nkmz
A2780ZD0473R MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTZ2LkdihKnDueLCiUOuNkDPxE1? MV6yOFIxQTZ7Mx?=
SKOV-3 NG[5Z5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLDdJBKSzVyPUSzMlTjiIoEsfMAjVMvQSEQvF2= MWOyOFIxQTZ7Mx?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pChK-2 / Chk-2 ; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated Chk-2. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ

p-p53(S15) / p-p53(S46) / p-p53(S392) / p53; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated p-p53. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ

p-p38 / p38 / Cleaved PARP / PARP ; 

PubMed: 30049957     


A2780s and A2780cp cells were treated with increasing concentrations of carboplatin for 48 h. Phosphorylation of p38 and cleavage of Poly(ADP-ribose) polymerase (PARP) were analyzed by Western blotting. Two antibodies were used to examine the cleaved PARP䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋Ð㺣痖�෋€𢡄�෋€䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemセ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒セ᎒�堞ﻮ᎒፲露𢡄

30049957
Immunofluorescence
γH2AX ; 

PubMed: 24348048     


Carboplatin induced DNA damage in SiHa cells. SiHa cells were exposed to 20, 40, and 80 μmol/L carboplatin for 12 hours, respectively. Immunofluorescence analysis was used to detect nuclear γ-H2AX foci formation with anti-H2AX antibody (red, fluorescein i䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ

24348048
Growth inhibition assay
Cell viability ; 

PubMed: 24348048     


SiHa and CaSki cells were treated with the indicated concentrations of carboplatin for 72 hours, and cell viability was measured by Cell Counting Kit-8 viability assay. 

24348048
In vivo In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Formulation: Carboplatin is dissolved in 43% ethanol, 33% polypropylene glycol and 24% cremaphor diluted 1:7 with sterile water.
  • Dosages: ≤60 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 14 mg/mL warmed (37.71 mM)
DMSO Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
14mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt

CAS No. 41575-94-4
Storage powder
in solvent
Synonyms JM-8, CBDCA, NSC 241240

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03968653 Recruiting Drug: Debio 0123|Drug: Carboplatin Advanced Solid Tumors Debiopharm International SA July 30 2019 Phase 1
NCT03723967 Recruiting Drug: Durvalumab with Carboplatin/Paclitaxel Squamous Cell Carcinoma of the Head and Neck Centre Leon Berard May 16 2019 Phase 2
NCT03694834 Suspended Drug: Pembrolizumab|Procedure: Hysterectomy Endometrial Cancer|Uterine Cancer UNC Lineberger Comprehensive Cancer Center|Merck Sharp & Dohme Corp. March 29 2019 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you advise what solvent to use and the concentration for S1215 for in vitro use?

  • Answer:

    DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Carboplatin | Carboplatin supplier | purchase Carboplatin | Carboplatin cost | Carboplatin manufacturer | order Carboplatin | Carboplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID